SureTrader Stock Hero Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Rexahn Pharmaceuticals, Inc. (RNN)

Add RNN Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 3/4/2015 12:10:08 PM - Followers: 201 - Board type: Free - Posts Today: 1


Rexahn’s goal is to be a world leader in the discovery and development of new drugs to treat cancer. By developing compounds which specifically target cancer cells, excluding healthy tissue, Rexahn’s drug candidates may demonstrate increased efficacy and reduced toxicity- efficacy against multiple drug resistant cancer cells and synergism with existing cytotoxic compounds. Utilizing a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling, nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.

Rexahn’s core scientific expertise in the understanding of signal transduction processes involved in cancer cell growth is producing a drug portfolio with significant potential clinical value.

Today, our clinical development pipeline consists of three novel compounds:

Archexin® (Phase IIa) a best-in-class compound that blocks both the activated and native forms of Akt1 and has FDA orphan drug designation for the treatment of pancreatic cancer, ovarian cancer, stomach cancer, RCC, and glioblastoma.

RX-3117 (Phase I) a best-in-class compound that inhibits DNA and RNA synthesis, and exhibits high oral bioavailability. In comparison, RX-3117 may have a better safety profile than gemcitabine, the current first-line therapy for pancreatic and other cancers.

SupinoxinTM (RX-5902) (Phase I) a first-in-class small molecule that inhibits the phosphorylated p68 RNA helicase, a protein that plays a key role in cancer growth, progression and metastasis.

These lead clinical drugs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant product pipeline of innovative medicines that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company- one with the expertise to develop cures for significant diseases of our time.

Rexahn Pipeline


Management Team

Peter Suzdak, Ph.D.
Chief Executive Officer

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University

Roth Capital Partners, LLC
   Joseph Pantginis, Ph.D.

Maxim Group, LLC
Echo He, MD, Ph.D.

H. C. Wainwright & Co., LLC
Andrew Fein

Tricia Truehart
(646) 378-2953

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
RNN News: Statement of Changes in Beneficial Ownership (4) 02/04/2015 04:49:21 PM
RNN News: Initial Statement of Beneficial Ownership (3) 02/04/2015 04:39:48 PM
RNN News: Current Report Filing (8-k) 02/04/2015 04:20:27 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 01/27/2015 06:46:00 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 01/27/2015 06:41:48 PM
News News Alert: Rexahn Pharmaceuticals to Present at the BIO-Europe Spring(R) 2015 Conference in Paris, France 03/04/2015 09:00:00 AM
#2928   Possible sleeper here could awaken soon. Eyes on it! harry crumb 03/04/15 12:10:08 PM
#2927   Charts getting primed. 50ma will cross 200ma within bud_fox 03/03/15 07:53:37 AM
#2926   it is my friend... load your machine Updated 03/02/15 10:02:48 PM
#2925   Check the chart below link: hopester 02/27/15 12:55:05 PM
#2924   Is it time? decouverte d Elbe 02/27/15 10:13:52 AM
#2923   Charts look primed for a breakout......I just don't DorianGray 02/27/15 08:38:48 AM
#2922   Y do u say that ttubular 02/26/15 10:28:58 PM
#2921   it's time my friend... it is about to Updated 02/26/15 09:21:32 PM
#2920   For what? kingsorcerer 02/26/15 09:20:48 PM
#2919   are you ready? Updated 02/25/15 10:26:22 PM
#2918   Could be accumulation but too early for any hopester 02/11/15 07:35:42 AM
#2917   I believe it is accumulation. Higher trading range johnkenny 02/10/15 10:00:01 PM
#2916   Action turned around. I was wrong, looks like decouverte d Elbe 02/10/15 04:48:06 PM
#2915   Sold early this morning. Conference was fine, but decouverte d Elbe 02/10/15 10:28:58 AM
#2914   Rexahn Pharmaceuticals to Present at the 17th Annual decouverte d Elbe 02/10/15 12:27:27 AM
#2913   Rexahn Pharma Offers Publication of Preclinical Data for decouverte d Elbe 02/10/15 12:25:33 AM
#2912   Benaim Ely decouverte d Elbe 02/10/15 12:23:38 AM
#2911   There was nice news today, but trading seemed decouverte d Elbe 02/10/15 12:12:56 AM
#2910   That's cool man. I hope they keep going $oldier Hard 02/09/15 10:31:22 AM
#2909   Rock Steady! Steady Rock! decouverte d Elbe 02/09/15 10:14:52 AM
#2908   Yes! I hope so to. .70-.75 range has Maverick587 02/09/15 10:00:12 AM
#2907   Should get some more loading in this range decouverte d Elbe 02/09/15 09:31:49 AM
#2906   Coincidence? Theo 02/03/15 09:25:28 AM
#2905   That's a healthy amount of shares for them. $oldier Hard 02/03/15 09:21:20 AM
#2904   Management exercised 1.766 million shares in stock options decouverte d Elbe 02/03/15 09:14:12 AM
#2903   Bought back in today at .725. $oldier Hard 01/28/15 11:48:10 PM
#2902   Hi everyone - still holding and just added tradinfool5 01/26/15 04:05:15 PM
#2901   I've been here for three years, patience is DorianGray 01/23/15 10:17:42 PM
#2900   I only heard it's now 50% a few decouverte d Elbe 01/23/15 12:34:40 PM
#2899   I agree, and am holding RNN, around this decouverte d Elbe 01/23/15 12:20:48 PM
#2898   I agree with most things you said, but pistol1p 01/23/15 12:20:13 PM
#2897   Dissecting my analysis of the recent price action, decouverte d Elbe 01/23/15 11:47:01 AM
#2896   Thank for taking time away from HEMP Inc pistol1p 01/22/15 10:38:57 PM
#2895   decouv > pistolpete secret time 01/22/15 09:39:47 PM
#2894   I was particularly intrigued by your 1% statement. pistol1p 01/22/15 08:40:21 PM
#2893   Let me add: hopester 01/22/15 07:21:12 PM
#2892   This is great! klbennie 01/22/15 06:52:18 PM
#2891   Again, I gave the reasons for my opinion, decouverte d Elbe 01/22/15 01:10:21 PM
#2890   Yes, you gave your reasons, but without any pistol1p 01/22/15 12:59:02 PM
#2889   I gave my reasons on why I believe decouverte d Elbe 01/22/15 12:25:13 PM
#2888   Yes, people give many reasons why they think pistol1p 01/22/15 09:34:59 AM
#2887   Please reread the previous post. I offered my decouverte d Elbe 01/22/15 06:36:48 AM
#2886   Please reread the previous post. pistol1p 01/21/15 08:47:19 PM
#2885   RNN is a good risk to move up decouverte d Elbe 01/21/15 03:00:19 PM
#2884   Eyes wide open and all I see is hopester 01/21/15 08:33:11 AM
#2883   Sounds far fetched, but a little reading and DorianGray 01/20/15 10:48:14 PM
#2882   That stretch takes the cake. Usually the shorts hopester 01/20/15 01:25:11 PM
#2881   As I previously mentioned big pharma pricks won't DorianGray 01/19/15 07:52:20 PM
#2880   Good support around these level. Would expect a hopester 01/16/15 01:02:17 PM
#2879   If rx3117 has good results at. 1000mg how ttubular 01/15/15 11:47:42 PM